# Five Forces Analysis of Pharmaceutical Raw Material

Rungpetch Sakulbumrungsil

March 28, 2024


+

C

# Outline of Presentation

- Current Situation of Pharma Industry
  - **OMarket**
  - Thailand ecosystem
- Active Pharmaceutical Ingredient
  - OMarket
  - Industrial analysis

### Characteristics of Pharma Industry





# Pharmaceutical Market Trend in Thailand

**CAGR** (Cum Annual Growth Rate)


Manufacture 10 & 34 yr2.48% / 8.09%

• Import 10 & 34 yr 6.43% / 13.70%





#### Proportion of new generic by local manufacturing and import in 2562



### Active Pharmaceutical Ingredients



SYNTHETIC CHEMICAL API

 Need imported starting material



**BIOTECHNOLOGICAL API** 

 Integrated with product development process



**EXTRACT OF NATURAL PRODUCTS** 

- Raw material is locally available
- GAP
- Health products, i.e., drugs, supplements, cosmetics

# Global Market Situation of API


#### Global API Value

- 212.07 Billion USD in 2022
- 312.37 Billion USD in 2028 (expected)
- CAGR 6.67% (2022-2028)

#### Market segmentation of API

- Generic Chemical API / Unpatented
  - China and India
- Patent recently expired / Biological API
  - India and Europe
- Originator API / Patented
  - Europe

### **TOP Spending ATC Groups**



### High Consumption Items

#### Antiinfection

- Meropenem
- Anti-retroviral

#### Cardiovascular

- Losartan
- Enalapril
- Amlodipine
- Simvastatin
- Atorvastatin

## Alimentary and metabolism

- Metformin
- Omeprazole
- Antacid

#### **Rivalry among Existing Competitors**

- China and India for generic API
- Europe for patented API
- Very few in Thailand
- Strong R&D
- Speed of entering the market
- Room for quality API

## POWER OF SUPPLIERS

#### **Bargaining Power of Suppliers**

- Depend on regulation
  - Starting material as drugs
- Need imported starting material

#### **Threat of Substitute Product**

- Many suppliers for Generic API
- Swtiching cost from regulation
  - Variation requires approval
- Generic API
  - Variation requires approval
- Availability of Drug Master File

## THREAT OF NEW ENTRANTS



THREAT OF SUBSTITUTE PRODUCTS

#### **Threat of New Entrants**

- Capital intensive investment
- Economy of scale
- No clear government policy
- Technology
  - o R&D
  - Starting Material
  - Quality

## POWER OF BUYERS

#### **Bargaining Power of Buyers**

- Depend on selected drugs
  - Orphan drug has few supplier
- Switching cost from regulation
  - Variation requires approval
- Availability of Drug Master File
- Price sensitivity
- Early availability of API

O

Pharmaceutical raw material are global market

Clear and aggressive government policy is needed to support the industry

Pharmaceutical excipients have a potential

# ขอบคุณค่ะ

